Skip to main content
CANbridge Pharmaceuticals Inc. logo

CANbridge Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · 1228 ISIN · KYG1821D1097 LEI · 8755009KKZM9ETBOF853 HKEX Manufacturing
Open in API
Filings indexed 191 across all filing types
Latest filing 2022-04-06 Share Issue/Capital Cha…
Country KY Cayman Islands
Listing HKEX 1228

About CANbridge Pharmaceuticals Inc.

http://www.canbridgepharma.com

CANbridge Pharmaceuticals Inc. is a global biopharmaceutical company focused on the research, development, and commercialization of transformative therapies for rare diseases and rare genetic conditions. The company leverages its foundation in China to deliver life-changing therapeutics globally. Its commercial portfolio includes approved products such as Hunterase® (a recombinant human Enzyme Replacement Therapy) and Livmarli (an oral inhibitor of the ileal bile acid transporter). CANbridge also maintains a pipeline of investigational therapies, including gene therapies, targeting high-impact indications in rare genetic diseases.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2022
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly return on movements in securities for an equity issuer listed on the Hong Kong Stock Exchange, specifically covering authorized share capital, issued shares, share options, and other share-related movements for the month ended 31 March 2022. It is a regulatory submission to the Hong Kong Exchanges and Clearing Limited, reporting on share capital and share issuance activities. It does not contain financial statements, earnings data, or management discussion, nor is it an announcement of a report publication. The content aligns with disclosures about share capital and share movements, which fits the category of Share Issue/Capital Change filings rather than a full financial report or other categories.
2022-04-06 English
CHANGE OF JOINT COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES
Board/Management Information Classification · 100% confidence The document is an announcement from CANbridge Pharmaceuticals Inc. regarding changes in the company's joint company secretary and authorised representative. It details the resignation of Mr. Keith Shing Cheung Wong and the appointment of Mr. Wai Chiu Wong, along with information about a waiver from strict compliance with certain listing rules. The content focuses on management personnel changes and compliance with listing rules, without any financial data or report content. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management roles. The document length (6431 characters) and detailed biographical information support this classification rather than a brief notice or regulatory filing.
2022-04-04 English
PROPOSED AMENDMENTS TO THE MEMORANDUM AND ARTICLES OF ASSOCIATION
Governance Information Classification · 95% confidence The document is an announcement by CANbridge Pharmaceuticals Inc. regarding proposed amendments to the company's Memorandum and Articles of Association. It references compliance with the Listing Rules of The Stock Exchange of Hong Kong Limited and details specific changes to governance documents. The content focuses on corporate governance structure and shareholder rights, not on financial results, audit, or other report types. The document is an announcement of proposed governance changes rather than the governance report itself. Given the detailed nature of the amendments to governance documents, this fits best under Governance Information (CGR). The document is lengthy and substantive, not a brief announcement or a certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA).
2022-03-23 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2021
Annual Report Classification · 95% confidence The document is titled 'ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2021' and contains detailed audited consolidated financial statements, including profit or loss, comprehensive income, and financial position for the year ended December 31, 2021. It includes extensive business highlights, financial highlights, and future developments, indicating a comprehensive yearly report. The presence of audited financials and detailed narrative aligns with an Annual Report (10-K equivalent) rather than a brief earnings release or announcement. The document length (15,000 characters) and content depth confirm it is the full report, not just an announcement of report availability. Therefore, the filing type is Annual Report (10-K). FY 2021
2022-03-23 English
NOTICE OF DATE OF BOARD MEETING
Report Publication Announcement Classification · 95% confidence The document is a short announcement from CANbridge Pharmaceuticals Inc. stating the date of a board meeting to consider and approve the annual results for the year ended December 31, 2021. It does not contain any financial data or the actual annual report but merely notifies the market of the upcoming board meeting where results will be approved and published. The document length is only 1424 characters, which is quite short and fits the pattern of a notice rather than a full report. According to the rules, such announcements about the timing of report approval or publication are classified as Report Publication Announcements (RPA).
2022-03-10 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2022
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities' and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued shares, share options, and other share-related information for the month ended 28 February 2022. The content focuses on share capital and share issuance movements rather than financial performance, management changes, or earnings. It is a regulatory submission related to share capital changes and share options, consistent with a share issue or capital change announcement. The document is not a full financial report, earnings release, or management discussion. Therefore, the most appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and detail support this classification with high confidence.
2022-03-04 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.